A Case of Helix-fixation Leadless Pacemaker Dislodgment and Retrieval: The Importance of Achieving Appropriate Post-Implant Impedance
The AVEIRTM (Abbott, Chicago, IL) helix-fixation leadless pacemaker (LP) system received the Food and Drug Administration approval in April 2022. The device has proven safety and efficacy in the LEADLESS II clinical trial.[1] We present a 93-year-old man who was admitted to the hospital with symptomatic sinus bradycardia. After shared decision making, the patient underwent AVEIR VRTM leadless pacemaker placement. Immediately after implantation, the device had dislodged. We detail a stepwise approach for retrieval and re-implantation, highlighting potential reasons for premature device migration and key points for successful implantation.